How to navigate diverse and changing IVDs regulations in the Asia Pacific region
This article was originally published in SRA
The regulatory landscape for in vitro diagnostics is changing rapidly the world over. Sandra Soniec provides a comprehensive summary of applicable regulations, classification systems and registration procedures across the Asia Pacific region.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.